RECOVERY Collaborative Group 2023, ' Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. ', Lancet (London, England), vol. 401, no. 10387, pp. 1499-1507 . https://doi.org/10.1016/S0140-6736(23)00510-X
Lancet (London, England) LANCET RECOVERY Collaborative Group 2021, ' Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY) a randomised controlled, open-label, platform trial ', The Lancet, vol. 397, no. 10289, pp. 2049-2059 . https://doi.org/10.1016/S0140-6736(21)00897-7 Mumford, A D 2021, ' Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised controlled, open-label, platform trial ', Lancet, vol. 397, no. 10289, pp. 2049-2059 . https://doi.org/10.1016/S0140-6736(21)00897-7 Group, RECOVERY C & Dark, P 2021, ' Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. ', Lancet (London, England), vol. 397, no. 10289, pp. 2049-2059 . https://doi.org/10.1016/S0140-6736(21)00897-7
Mumford, A D & Gibbison, B J J 2022, ' Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial and updated meta-analysis ', Lancet, vol. 400, no. 10349, pp. 359-368 . https://doi.org/10.1016/S0140-6736(22)01109-6 Dimitriadis, G K 2022, ' Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial and updated meta-analysis ', Lancet, vol. 400, no. 10349, pp. 359-368 . https://doi.org/10.1016/S0140-6736(22)01109-6 RECOVERY Collaborative Group & Dark, P 2022, ' Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis ', Lancet . https://doi.org/10.1016/S0140-6736(22)01109-6
RECOVERY Collaborative Group & Downey, D 2022, ' Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial ', The Lancet, vol. 399, no. 10325, pp. 665-676 . https://doi.org/10.1016/S0140-6736(22)00163-5 Mumford, A D 2022, ' Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial ', Lancet, vol. 399, no. 10325, pp. 665-676 . https://doi.org/10.1016/S0140-6736(22)00163-5 Lancet (London, England) Group, RECOVERY C, Felton, T, Dark, P & Mathioudakis, A 2022, ' Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial ', Lancet (London, England), vol. 399, no. 10325, pp. 665-676 . https://doi.org/10.1016/S0140-6736(22)00163-5